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Abstract The enzyme cyclooxygenase 2 is an inducible en-
zyme expressed at sites of inflammation and in a variety of
malignant solid tumors such as endometrial cancer (EC). In
EC patients, its over-expression is correlated with progressive
disease and poor prognosis. The expression is encoded by a
polymorphic gene, called PTGS2. The aim of the current
study was to test the hypothesis that rs5275 polymorphism
of PTGS2 influence the prognosis of EC patients. This paper
is a retrospective cohort study. Clinical and pathological data
were extrapolated and genotypes were assessed on formalin-
fixed and paraffin-embedded non-tumor tissues. A total of 159
type I EC patients were included in the final analysis.
Univariate analysis indicated that patients with rs5275 geno-
type CC have a lower risk to develop a grade (G) 2–3 endo-
metrial cancer. rs5275 effect on EC grading was confirmed by
multivariate analysis also after data adjusting for age, BMI,
parity, hypertension, and diabetes. Adjusted odds ratio (OR)
confirmed that patients with rs5275 genotype CC have a risk
80 % lower (OR=0.20, P=0.009) to develop a G2 and/or G3
EC in comparison with patients with TT or TC genotype.
Differentiation of the type 1 EC is significantly and indepen-
dently influenced by rs5275 polymorphism. rs5275 CC pa-
tients have a lower risk to present a G2–G3 EC.
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Introduction
Endometrial cancer (EC) is the most common gynecological
malignancy in developed countries, and 287,000 new cancer
cases and 74,000 cancer deaths worldwide were recorded in
the 2008 [1–4].
Two types of EC has been reported. Type I is the most
common EC, it is an endometrioid adenocarcinoma that can
be classified into highly differentiated (G1), moderately dif-
ferentiated (G2), or undifferentiated (G3) according to FIGO
classification. Usually, type I EC is a G1 tumour that is diag-
nosed at an early stage and is characterized by a good prog-
nosis. Type II EC includes more aggressive histotype and is
associa ted with worse prognosis [1] . Prolonged
hyperestrogenism, unopposed by progesterone, has a pivotal
role in the pathogenesis of type I EC. Hyperestrogenism char-
acterizes early menarche, late menopause, nulliparity, estro-
gen only hormone replacement therapy and obesity that are
well-known risk factors for type I EC [5, 6].
Single nucleotide polymorphisms (SNPs) of many genes
related to sex steroid hormone metabolism pathway has been
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associated with an increased risk for EC [7]. SNPs of aroma-
tase (CYP19A1) influenced susceptibility to EC, particularly
among older and obese patients [7]. However, very little of the
genetic risk related to these SNPs is actually known.
Recent data suggested that chronic inflammation cooper-
ates with hyperestrogenism in the development of type I EC
[8, 9]. Consequences of chronic inflammation are cell prolif-
eration, inhibition of apoptosis, and desoxyribonucloproteic
acid (DNA) damage [10]. Mediators of the inflammatory re-
sponse, such as the enzyme cyclooxygenase (COX), produce
prostaglandins (PGs) which together with inflammatory cyto-
kines may suppress the cell-mediated immune responses and
promote angiogenesis [10].
COX is the late-limiting enzyme that catalyzes the initial
step in the biosynthesis of PGs from arachidonic acid [11].
Two different COX isoforms exist. COX-1 is a constitution-
ally expressed isoform, while COX-2 is an inducible enzyme
expressed at sites of inflammation and in a variety of malig-
nant solid tumors, such as colorectal, gastric, esophageal, pan-
creas, lung, breast, and EC [12]. The expression of COX-2
was increased in EC, and was associated with the inhibition of
apoptosis and the promotion of angiogenesis [13].
In several studies, COX-2 expression was associated with
tumor cell differentiation and prognosis. It was demonstrated
that in hepatocellular, lung, and ovarian carcinoma [14–16],
well-differentiated tumors have higher COX-2 concentration
than poorly differentiated ones.
Opposite data were obtained by other studies conducted on
oral, hypopharyngeal and bladder cancer. In these cases COX-
2 expression was demonstrated to be significantly higher in
poorly differentiated tumors and associated with poor progno-
sis and advanced stage [17–19]
COX-2 is encoded by a polymorphic gene, called PTGS2.
COX-2 expression might be influenced by variant alleles locat-
ed in the promoter region, next to binding sites for transcription
factors [14, 15], and in the 3′-untranslated region, in regions
involved with the maintenance of mRNA stability [16, 20].
The association between the T8473C (rs5275) polymor-
phism of COX-2 gene and the increased risk of tumors, often
characterized by COX-2 overexpression [21–33], was de-
scribed in several original articles.
Rs5275 SNP resides within the 3′UTR sequence of COX-2
gene and that region was described to target COX-2 mRNA
for degradation through micro-RNA-mediated regulation.
In vitro miR-542-3p was demonstrated to regulate COX-2
expression. In particular, in Hela and colorectal cancer cell,
miR-542-3p binds transcripts derived from rs5275 Tallele and
consequently promotes COX-2 mRNA decay, while the pres-
ence of C allele interferes with this miRNA allowing mRNA
stabilization and COX-2 higher expression [34].
Although the role of COX-2 in the pathogenesis of EC is
well known, no data investigated the association between
PTGS2 SNPs and EC prognosis. Based on previous
assumptions, this study was aimed to evaluate the association
between the rs5275 SNP of PTGS2 and the clinical and path-
ological characteristics of patients with type I EC in order to
assess its prognostic value on clinical outcomes.
Methods
Patient samples
The study was designed following the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) statement [35]. The Local Ethical Committee ap-
proved the study design, and all patients provided written
informed consent to use personal non-sensitive data at hospital
admission.
Clinical charts of EC patients treated and followed at the
IRCCS - Santa Maria Nuova Hospital of Reggio Emilia (Italy)
from 1997 to 2010 were checked for inclusion and exclusion
criteria. Tissue samples of the included patients were re-
trieved, prepared, and stored in the tissue storage system of
the Department of Pathology. Genomic DNA extraction and
purification, and rs5275 genotyping were then performed in
the Laboratory of Molecular Biology.
Clinical, pathological, and genetic data were recorded in an
electronic separate, anonymous, password-protected database.
All relevant data were extrapolated and used for final analysis.
Patients with histological diagnosis of type I, endometrioid
ECwho received upfront adequate surgery treatment were elec-
tively included in the protocol study. Exclusion criteria were as
follows: histological diagnosis of type II (non endometrioid
tumors) EC, inadequate EC management according to internal
and international guidelines [36, 37], neoadjuvant chemother-
apy performed before surgery, an age less than 18 years, non-
Caucasian ancestry, a follow-up length shorter than 6 months,
inadequate follow-up according to internal guidelines, absence
of written informed consent, diagnosis of a previous or concur-
rent cancer(s), and unavailable follow-up data.
An Badequate^ management was considered as follows:
total extrafascial hysterectomy (TEH) with bilateral
salpingo-oophorectomy (BSO) was the standard staging pro-
cedure, whereas radical hysterectomy (RH) was performed
only in stage II EC patients with gross cervical involvement;
pelvic with/without paraaortic lymph node dissection were
performed in case of myometrial invasion greater than 50
percent, large tumor (>2 cm in diameter) or filling the endo-
metrial cavity. Vaginal brachytherapy alone was administered
to patients at stage IA G3 and IB G1 or G2 without neg-
ative prognostic factors. External beam radiotherapy plus
vaginal brachytherapy was administered to patients at stage
IA G3 and IB G1 and G2 with negative prognostic factors,
and to patients at stage IB G3 and to all patients at stage II,
III, and IV. Chemotherapy was administered to patients at
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stage III C and IV. In all cases, chemoradiotherapy consisted
of paclitaxel 175 mg/m2 (P) and carboplatin AUC5 (C) on day
1 every 3 weeks, for a total of four to six cycles, and it was
followed by external pelvic radiation therapy (1.8 Gy/d, d1-5)
at a total dose of 45 Gy plus vaginal brachytherapy (3×5 Gy)
[36, 38].
A follow-up was defined Badequate^ in case of adherence
to the following schedule: type I EC at stage IA and grading
G1/G2—physical and gynecological examination, and
transvaginal ultrasound every 6 months for the first 2 years,
and then every 12 months for at least 3 years; type I EC at
stage IB and/or any grading G3 tumor—physical and gyneco-
logical examination, and transvaginal ultrasound every
6 months for the first 5 years. Further investigations such as
abdominal ultrasound, chest X-ray, computed tomography
scan, and serum CA 125 levels were performed if clinically
indicated.
The same pathologist (M.C.G.) with long-time expertise in
gynecological oncology reviewed all the histological samples
in order to confirm formally the diagnosis.
DNA extraction and genotyping
Two operators (E.F, B.C.) performed the genomic DNA ex-
traction and purification from five 5-μm-thick slices of
formalin-fixed and paraffin-embedded non-tumor tissue using
the BiOstic® FFPE Tissue DNA Isolation Kit (MoBio
Laboratories, Inc., Carlsbad, CA). DNAwas quantified using
Nanodrop 2000 (Thermo Scientific).
Rs5275 genotyping was performed in service by LGC
Genomics/KBioscience (Hertfordshire, UK) using KASP™
genotyping assay, which employs a competitive allele-
specific PCR (http://www.Kbioscience.co.uk). The major
and minor alleles of rs5275 SNP were defined as T and C,
respectively.
Immunohistochemistry
Histological slides were evaluated for the expression of COX-2.
Immunohistochemistry was performed on formalin fixed,
paraffin embedded, 5-μm-thick EC tissue sections. Staining
was performed using a Benchmark XT autoimmunostainer
(Ventana Medical Systems, Tucson, Arizona).
After deparaffinization and hydration, Heat-Induced
Epitope Retrieval (HIER) was performed on slides inside the
system using CC2 buffer (low pH buffer). Rabbit polyclonal
primary anti-COX-2 antibody (Novus Biologicals, Littleton,
Colorado) was used at dilution of 1:50 and applied to tissue
sections and incubated at room temperature for 24 min.
Detection was performed using the Ultraview DAB detection
Kit (Ventana Medical Systems, Tucson, Arizona), which uses
3,3′-diaminobenzidine (DAB) as chromogen. AVentana am-
plification kit was used for increasing the signal.
As positive control, a section of colon carcinoma, with a
clear cytoplasmic positivity, was used.
As negative control, a section ofmyometrial healthy tissues
was used.
Statistical analysis
Parametric data were expressed as median and range. Fisher
test was used to investigate univariate and multivariate asso-
ciation between rs5275 and clinical and pathological
parameters.
The overall survival (OS) was computed as the time period
from the date of surgery to either the date of death or last
follow up, whichever occurred first. Cox regression hazard
model was used to evaluate the effect of each parameter on
overall survival, and results were presented as hazard ratio
(HR). For statistical analysis, R-2.15.1 software was used.
Significant statements referred P values of two-tailed tests that
were less than 0.05.
Results
After patients’ selection for the inclusion and exclusion
criteria, a total of 159 EC patients were studied and included
in the final analysis. Total extrafascial hysterectomy was per-
formed in 150 (94.3 %) patients, whereas radical hysterecto-
my was performed in 9 (5.7 %) patients. Salpingo-
oophorectomy was performed in 151 (95 %) patients.
Omentectomy and appendicectomy were performed in 17
(10.7 %) and 4 (2.5 %) patients, respectively. Eighty-two
(51.6 %) patients received pelvic lymphadenectomy and only
8 (5 %) patients received lombo-aortic lymphadenectomy. In
all patients, a complete resection of the disease was obtained.
After a median follow-up time of 67 months (range, 7 to
151 months), a total of 9 patients died. For the patients who
died, the median overall survival was 44 months (range, 7 to
61 months).
In our population, the frequency of major allele Tof rs5275
polymorphism was 67.6 %. Genotypes TT, TC, and CC were
found, respectively, in 45.2 % (72/159 patients), 44.7 % (71/
159 patients), and 10.1 % (16/159 patients) of the studied
population. That genotypic distribution of polymorphism re-
sulted in Hardy-Weinberg equilibrium (P=0.81).
Table 1 shows the univariate association between rs5275
polymorphism and clinical and pathological characteristics.
An influence of rs5275 CC genotype on EC grading was
detected (P=0.02). A significant (P=0.03) association be-
tween TC genotype and the patients’ age was also observed.
However, no significance was detected considering homozy-
gous genotypes. Our data didn’t show any significant effect of
rs5275 on overall survival (Table 1).
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An analysis of the best-fitting genetic model that sup-
port a potential association between rs5275 polymorphism
and the tumor grading was performed (Table 2), and uni-
variate analysis suggested the adequacy of the recessive
model. Genetic recessive model indicated that only in pa-
tients with both C allele, the rs5275 genotype was signif-
icantly associated with a lower risk to develop a grade
G2-G3 poorly differentiated EC while the presence of an
heterozygous genotype with only a C allele was not suf-
ficient to substantially influence the risk.
Rs5275 effect on EC grading was confirmed by multivar-
iate analysis also after data adjustment for age, BMI, parity,
hypertension, and diabetes (Table 3). Adjusted OR confirmed
that patients with rs5275 genotype CC have an 80 % lower
risk (OR 0.20, P=0.009) to develop a G2 and/or G3 EC in
comparison with patients with TT or TC genotype (Table 3).
Table 1 Study of the association between rs5275 genotypes and principal clinical and pathological characteristics of the type I EC population analyzed
Rs5275 genotype Overall survival
Characteristics Patients TT P value TC P value CC P value # Death HR P value
(n%) (N=159) (n%) (N=72) (n%) (N=71) (n%) (N=16)
Age
≤64 82 (51.6) 30 (41.7) 43 (60.6) 9 (56.2) 2
>64 77 (48.4) 42 (58.3) – 28 (39.4) 0.0247* 7 (43.8) 0.2920 7 4.02 0.082
BMI
≤28 85 (53.5) 39 (54.1) 39 (54.9) 7 (43.7) 3
>28 74 (46.5) 33 (45.9) – 32 (45.1) 0.927 9 (56.2) 0.452 6 2.60 0.177
Parity
No 24 (15.1) 12 (16.6) 9 (12.7) 3 (18.7) 1
Yes 135 (84.9) 60 (83.4) – 62 (87.3) 0.501 13 (81.2) 0.841 8 1.51 0.699
Hypertension
No 76 (47.8) 37 (51.4) 33 (46.5) 6 (37.5) 2
Yes 83 (52.2) 35 (48.6) – 38 (53.5) 0.557 10 (62.5) 0.318 7 4.06 0.081
Diabetes mellitus
No 128 (80.5) 60 (83.3) 57 (80.3) 11 (68.7) 7
Yes 31 (19.5) 12 (16.7) – 14 (19.7) 0.636 5 (31.3) 0.189 2 1.25 0.779
Figo stage1
I–II 145 (91.2) 65 (90.3) 64 (90.1) 16 (100) 7
III–IV 14 (8.8) 7 (9.7) – 7 (9.9) 0.978 0 (0) nd 2 3.03 0.166
Grading
G1 69 (43.4) 30 (41.8) 27 (38.0) 12 (75.0) 3
G2–G3 90 (56.6) 42 (59.2) – 44 (62.0) 0.2069 4 (25.0) 0.0216* 6 1.54 0.541
Myometrial invasion
<50 % 89 (56.0) 35 (48.6) 42 (59.2) 12 (75.0) 2
>50 % 70 (44.0) 37 (51.4) – 29 (40.8) 0.2069 4 (25.0) 0.0642 7 4.58 0.058
Adjuvant treatment
None 109 (68.6) 45 (62.5) 48 (67.6) 16 (100) 6
Radiotherapy 38 (23.9) 21 (29.2) 17 (23.9) 0 (0) 1 0.52 0.542
Chemo-Radiotherapy 12 (7.5) 6 (8.3) – 6 (8.5) 0.5223 0 (0) nd 2 3.30 0.143
Lymph node metastasis
(108 lymphadenectomy)
108 48 51 9
No 100 (92.6) 43 (89.6) 48 (94.1) 9 (100) 8
Yes 8 (7.4) 5 ( 10.4) – 3 (5.9) 0.414 0 (0) nd 1 1.59 0.662
Rs5275 genotype
TT 72 (45.3) 4
TC 71 (44.6) 3 0.73 0.687
CC 16 (10.1) 2 2.51 0.289
Last three columns of the table indicate that none of the characteristics analyzed can be significantly associated to patients’ overall survival
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Immunohistochemistry was used to evaluate COX-2
protein localization in EC tissues and its expression in
patients with different rs5275 genotypes. Staining con-
firmed COX-2 protein expression in tumor tissues
(Fig. 1a–g) while myometrial healthy tissue (Fig. 1h)
resulted unstained.
To evaluate the effect of polymorphism on COX-2 protein
expression in EC tissues, excluding possible influences by
tumor grading, only samples from G1 EC with different
r s5275 geno types were examined , (F ig . 1a–c ) .
Immunohistological cytoplasmic staining of COX-2 resulted
to be variable among G1 EC samples. In particular, rs5275 TT
genotype tissues (Fig. 1a) showed generally a higher staining
compared with TC and CC samples who exhibited respective-
ly medium, with varying degrees of intensity in the cytoplasm
of tumour cells (TC genotype) (Fig. 1b) and low or absent
staining (CC genotype) (Fig. 1c).
Immunohistochemistry was also used to investigate the ex-
pression of COX-2 protein in different grades of endometrioid
cancer. To do that, excluding possible rs5275 SNP effects, only
TT genotype EC tissues with different grading were examined
(Fig. 1d–f). Images demonstrated that the intensity of staining
was correlated with tumor grade, and the highest and
omogeneous staining was observed in G3 tumour cells (Fig 1d).
Discussion
To our knowledge, this was the first study aimed to test the
hypothesis that the COX-2 encoding polymorphic gene
PTGS2 influences the histopathological variables of type I
EC. In particular, current findings demonstrated that the tumor
grading of EC varies significantly according to rs5275 geno-
types. In fact, CC genotyped patients showed a lower risk to
Table 2 Analysis of the best-
fitting genetic model that support
an association between rs5275
polymorphism and the grade of





OR (95%CI) P value
Genotype
T/T 30 (43.5) 42 (46.7) 1 –
C/T 27 (39.1) 44 (48.9) 1.16 (0.59–2.28) 0.657
C/C 12 (17.4) 4 (4.4) 0.24 (0.06–0.76) 0.022*
Dominant model
T/T 30 (43.5) 42 (46.7) 1 –
C/T+C/C 39 (56.5) 48 (53.3) 0.89 (0.47–1.65) 0.689
Recessive model
T/T+C/T 57 (82.6) 86 (95.5) 1 –
C/C 12 (17.4) 4 (4.4) 0.22 (0.06–0.67) 0.012*
ORs and P value are obtained from an unadjusted Fisher test
Table 3 Study of the association of clinical and genetic features with the grade of type I EC tumors





P value(n%) (N=69) (n%) (N=90) (95 % CI)
Age (years) ≤64 40 42 – 1 –
>64 29 48 1.58 (0.84–2.98) 0.158 1.36 (0.68–2.72) 0.376
BMI ≤28 40 45 1 –
>28 29 45 1.38 (0.73–2.61) 0.319 1.37(0.68–2.76) 0.378
Parity No 13 11 1 –
Yes 56 79 1.67 (0.70–4.06) 0.251 1.46 (0.59–3.67) 0.413
Hypertension No 38 38 1 –
Yes 31 52 1.68 (0.89–3.17) 0.109 1.53 (0.75–3.16) 0.241
Diabetes mellitus No 56 72 1 –
Yes 13 18 1.08 (0.49–2.42) 0.855 0.94 (0.39–2.32) 0.892
rs5275_recessive model T/T+C/T 57 86 1 –
C/C 12 4 0.22 (0.06–0.67) 0.012* 0.20 (0.05–0.63) 0.009*
Crude ORs and P values are obtained using unadjusted Fisher tests. Adjusted ORs and P values are obtained frommultivariate analysis were all features
were fitted together
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have G2–G3 poorly differentiated EC. On the other hand,
rs5275 SNP genotype could be hypothesize to be an indepen-
dent protective factor for high-grade type I EC.
In order to explore that influence, our population was stud-
ied according to well-known risk factors such as age, BMI,
parity, diabetes, and hypertension. Age was significantly as-
sociated with EC grade at univariate analysis; older patients
presentedmore G2–G3EC.However, at multivariate analysis,
only rs5275 genotype showed an influence on EC grade.
Tumor grade represents a well-established risk factor, ac-
cording to tumor grade staging procedure such as systematic
lymphadenectomy, and adjuvant treatment are performed or
not [38]. Moreover, with the widespread of fertility sparing
surgery that can be proposed only in case of type 1 G1 EC at
stage 1 [38], to know that the risk of G2-G3 EC is genetically
reduced might be reassuring.
Although the role of COX-2 in the pathogenesis of EC is
well known, no data exist about rs5275 genotype and EC.
Some information comes from studies on breast and ovarian
cancer. Breast cancer is an estrogen-dependent tumor, such as
EC type 1, in which the main secretory factor inducing aro-
matase expression in the surrounding stromal cells is the pros-
taglandin E2 (PGE2) that is synthetized by COX-2 [39]. In
breast cancer, the presence of rs5275 T in a certain haplotype
might be a risk factor in relation to the growth of untreated
breast cancers [40].
Moreover, CC rs5275 genotype was significantly associat-
ed with a reduced risk of ovarian cancer particularly among
carriers of the CC genotype who were users of non-aspirin
non-steroidal anti-inflammatory drugs [32]. About non-
gynecological cancers, CC genotype was associated with a
reduced risk of lung cancer [41]. On contrary, variant allele
Fig . 1 Immunoh i s t o chemi s t r y i n EC FFPE t i s s ue s . a
Immunohistochemical stain for COX-2 in G1 EC tissue with rs5275 TT
genotype, ×200 magnification . b Immunohistochemical stain for COX-2
in G1 EC tissue with rs5275 TC genotype, ×200 magnification. c
Immunohistochemical stain for COX-2 in G1 EC tissue with rs5275
CC genotype, ×200 magnification. d Immunohistochemical stain for
COX-2 in G3 EC tissue with rs5275 TT genotype, ×200 magnification.
e Immunohistochemical stain for COX-2 in G2 EC tissue with rs5275 TT
genotype, ×200 magnification. F Immunohistochemical stain for COX-2
in G1 EC tissue with rs5275 TT genotype, ×200 magnification. g Positive
control: Immunohistochemical stain for COX-2 in colorectal cancer
tissue, ×400 magnification. h Negative control: Immunohistochemical
stain for COX-2 in myometrial healthy tissue, ×400 magnification
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C of rs5275was significantly associated with an increased risk
of gastric cancer particularly in females and no smokers [42],
and was associated with an increased risk of esophageal ade-
nocarcinoma in Caucasian population [43]. In addition, C al-
lele was found to be significantly associated with diagnosis of
hereditary non-syndromic colorectal cancer and an earlier age
of diagnosis. Interestingly, female CC rs5275 carriers were
diagnosed less when young, but by 60 years of age were the
most at risk group [33].
In Hela and colorectal cancer cells, rs5275 was demonstrat-
ed to favor COX-2mRNA stabilization and consequent COX-
2 higher expression interfering with miR-542-3p binding [34],
but to our knowledge, the effect of this miRNA on COX-2
expression was not investigated in other tissues in association
to rs5275 SNP. Several studies associated COX-2 expression
to the grade of differentiation of tumor cells, but contrasting
data could suggest a various involvement of COX-2 protein in
different sites of cancer [14–19].
Our preliminary data obtained by immunohistochemistry
suggested a correlation between COX-2 protein expression
and the grade of differentiation in endometrioid cancer. A
higher intensity of staining was observed in G3, poorly-differ-
entiated, EC tumors.
In the current study, rs5275 CC genotype was significantly
associated with a higher frequency of G1 well-differentiated
tumors. Preliminary data obtained from immunohistochemis-
try suggested a reduced level of COX-2 protein in tumor tis-
sues from patients with CC genotype in comparison with
grade equivalent cancer tissues from patients with TT/CT
genotypes.
Basing on these initial observations, we suppose that type 1
EC tissues of patients with rs5275 TT/CT genotype could be
characterized by COX-2 up-regulation that resulting in en-
hanced synthesis of prostaglandins, high levels of inflamma-
tion and cell proliferation could support the development of
less-differentiated tumors. However, further experiment
would be necessary to confirm our hypothesis, and no data
are available about the way the polymorphism rs5275 can
regulate COX-2 expression in endometrial cancer.
The strength of our study concern the selection of a very
homogeneous population of type I EC patients who received
an upfront surgery with adequate management and follow-up
length. The centralization of treatment, of follow-up, and of
pathology review are further study strengths that ensured a
uniformity of treatment, of staging procedures, post-
treatment monitoring, and of histological classification.
Instead, in other available studies, the treatment and follow-
up protocols widely varied [44, 45]. Moreover, our study has
also important limitations. Firstly, it had a retrospective de-
sign, and the potential and related biases/confounders are well
known. Secondly, it might be underpowered due to the small
cohort studied, and current sample size might not be sufficient
to detect a synergistic effect in a replicate study.
In conclusion, current preliminary analysis demonstrates
that the differentiation of the type 1 EC is significantly and
independently influenced by rs5275 polymorphism. Rs5275
CC patients have a lower risk to present a G2-G3 EC.
However, further large multicenter studies need to confirm
our results, and to assess whether the knowledge of the
rs5275 polymorphism might be useful for patients’ selection
and for management personalization of type 1 EC patients.
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